logo
Plus   Neg
Share
Email

Mylan, Biocon Announce US Launch Of Trastuzumab Biosimilar Ogivri - Quick Facts

Pharmaceutical company Mylan N.V. (MYL) and India-based Biocon Ltd. announced Monday the U.S. launch of Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab). The product is co-developed by Mylan and Biocon.

Ogivri was the first biosimilar trastuzumab approved by the U.S. Food and Drug Administration (FDA) and unanimously recommended by the FDA Oncologic Drugs Advisory Committee (ODAC). Ogivri is available in a 420mg multi-dose vial and a 150mg single-dose vial in order to provide patient dosing and treatment flexibility.

Ogivri is approved for all indications of Herceptin including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

Two supplemental Biologics License Applications were recently approved by the FDA, expanding the manufacturing capability for Ogivri, as well as Mylan and Biocon's first U.S. biosimilar, Fulphila, a biosimilar to Neulasta.

Mylan and Biocon Biologics have sufficient manufacturing capacity to fulfill demand in the U.S. and global markets for both products.

FDA approval of Ogivri was based on robust data demonstrating that Ogivri is highly similar to Herceptin and no clinically meaningful differences exist between the biosimilar product and Herceptin in terms of safety, purity and potency

Long-term results of the landmark HERITAGE study including overall survival data at 36 months were presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting.

Ogivri is the second biosimilar to be offered by Mylan through the Mylan-Biocon Biologics partnership in the U.S. and the second FDA-approved biosimilar through this collaboration to support cancer patients. Mylan and Biocon launched the world's first biosimilar trastuzumab in India in 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Marathon Petroleum Corp. (MPC) Wednesday reported a sharp fall in fourth quarter net profit attributable to MPC to $443 million, or $0.68 per share from $951 million, or $1.35 per share last year. Non controlling interests for the quarter was a loss of $201 million, while it recorded a profit of $224... Swiss drug major Novartis AG reported Wednesday that its fourth-quarter net profit declined, while operating income climbed on strong sales growth. Looking ahead, for fiscal 2020, the company expects net sales to grow mid to high-single digit and core operating income to grow high-single to low double digit, both in constant currency. Starbucks on Tuesday said it has closed more than half of its stores in China temporarily due to the worsening coronavirus outbreak that claimed around 132 lives in the country. The coffee giant is also monitoring and modifying the operating hours of all of its stores in the region.The closed store count would be more than 2000 as Starbucks operates almost 4,300 outlets in China.
Follow RTT
>